BackThermo Fisher Scientific Overview
Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Target Price

Where could TMO trade next? Consensus target price: $580.

Get informed when a big investor buys or sells

+ Follow

Share Price

$574.3

Average Target Price

$579.080.8% upside

12 analysts in the last 4 months

High: $650 | Low: $490

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-27Piper Sandler$6004.5% upsideOpen
2026-07-24Morgan Stanley$65013.2% upsideOpen
2026-07-24RBC CapitalDan Leonard$5801% upsideOpen
2026-07-23JefferiesTycho Peterson$6309.7% upsideOpen
2026-07-06Evercore ISI$5700.7% downsideOpen
2026-06-26Bernstein$5209.5% downsideOpen
2026-06-11Piper Sandler$51011.2% downsideOpen
2026-06-03HSBCSidharth Sahoo$5406% downsideOpen
2026-05-14RBC Capital$49014.7% downsideOpen
2026-04-27Morgan StanleyKallum Titchmarsh$6208% upsideOpen
2026-04-24Stifel NicolausDaniel Arias$6004.5% upsideOpen
2026-04-24Robert W. BairdCatherine Ramsey Schulte$63911.3% upsideOpen
2026-01-30UBS$6157.1% upsideOpen
2026-01-30Wells Fargo$68318.9% upsideOpen
2026-01-30Robert W. Baird$65313.7% upsideOpen
2026-01-30Barclays$65013.2% upsideOpen
2026-01-09Stifel NicolausDaniel Arias$70021.9% upsideOpen
2026-01-05Evercore ISIVijay Kumar$65013.2% upsideOpen
2025-12-15Wells Fargo$67517.5% upsideOpen
2025-12-09Goldman SachsEvie Koslosky$68519.3% upsideOpen
2025-12-07KeyBancPaul Knight$75030.6% upsideOpen
2025-10-29Argus Research$6106.2% upsideOpen
2025-10-28Morgan Stanley$65614.2% upsideOpen
2025-10-23UBS$5902.7% upsideOpen
2025-10-23Barclays$6258.8% upsideOpen
2025-10-22Leerink Partners$5801% upsideOpen
2025-10-08Redburn Partners$5750.1% upsideOpen
2025-10-08Redburn Partners$5801% upsideOpen
2025-10-02BarclaysLuke Sergott$5851.9% upsideOpen
2025-09-02RBC CapitalConor McNamara$5612.3% downsideOpen
2025-07-08UBSDan Leonard$46019.9% downsideOpen
2025-04-25Scotiabank$6055.3% upsideOpen
2025-04-23Goldman SachsMatthew Sykes$6106.2% upsideOpen
2025-01-31RBC CapitalConor McNamara$69320.7% upsideOpen
2025-01-02Evercore ISIVijay Kumar$5851.9% upsideOpen
2024-10-24Robert W. BairdCatherine Schulte$6228.3% upsideOpen
2024-10-23BarclaysLuke Sergott$6106.2% upsideOpen
2024-10-01Evercore ISIVijay Kumar$6309.7% upsideOpen
2024-09-20Stifel NicolausDaniel Arias$68018.4% upsideOpen
2024-09-20Robert W. BairdCatherine Schulte$63210% upsideOpen
2024-09-19CitigroupPatrick Donnelly$6208% upsideOpen
2024-09-18Deutsche BankJustin Bowers$6309.7% upsideOpen
2024-09-16Bank of America SecuritiesDerik de Bruin$67517.5% upsideOpen
2024-07-25Raymond JamesAndrew Cooper$66014.9% upsideOpen
2024-06-28BarclaysLuke Sergott$6004.5% upsideOpen
2024-04-30HSBCSidharth Sahoo$67016.7% upsideOpen
2024-04-25Deutsche BankJustin Bowers$6106.2% upsideOpen
2024-04-25BarclaysLuke Sergott$6157.1% upsideOpen
2023-12-28Robert W. BairdCatherine Schulte$67016.7% upsideOpen
2023-10-26Raymond JamesAndrew Cooper$5307.7% downsideOpen

Thermo Fisher Scientific (TMO) FAQ

Thermo Fisher Scientific's target price stands at $580. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $580 for TMO implies 0.8% upside versus today's price ($574.3). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Thermo Fisher Scientific's target price evolved across reporting periods, while the comparison chart places TMO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Thermo Fisher Scientific's reading of $580 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.